Oral lenacapavir
Gilead Sciences · HIV pre-exposure prophylaxisFeb 2, 2027 target
Will the FDA approve Oral lenacapavir for HIV pre-exposure prophylaxis?
Outcome claim / Research candidate
No market price yet.
This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.
This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.
Rx-GILD-2702 / Evidence
UnlistedA pool price describes trading inventory; a model estimates an outcome. Neither a live price nor a dated forecast is available for this unlisted catalyst.
Program overview
Sponsor reports acceptance for a once-weekly oral PrEP formulation, with a February 2, 2027 FDA target.
No reviewed probability or reasoning artifact is available. A neutral pool opening is not a clinical base rate.
What matters
- Existing twice-yearly injectable approval is not approval of this weekly oral formulation; ticker stock hedge is especially noisy.
- Approval, the stock price and commercial success are different outcomes. A claim only pays on its specified event.
- Future program funding and tokenized financing require separate rights and contracts. An event claim gives no equity, royalty or drug IP.